Nature Biotechnology, November 2009 by Sarah Webb
http://www.nature.com/nbt/journal/v27/n11/full/nbt1109-977.html

“You have the tension that this just looks like a really attractive technology to commercialize. Then you have the challenge that we’re not clear on what we can patent or what we can’t patent,” says Ken Taymor, executive director of the Berkeley Center for Law, Business and the Economy in California.

Nature News, April 22, 2009 by Monya Baker
http://www.nature.com/news/2009/090419/full/458962a.html

With more and more methods being published, the intellectual-property situation is “more complicated than for human embryonic stem cells by an order of magnitude,” says Ken Taymor, director of the Berkeley Center for Law, Business and the Economy in California.

Los Angeles Times, March 30, 2009 by Michael Hiltzik
http://www.latimes.com/business/la-fi-hiltzik30-2009mar30,0,3108872.column

Lacking any truly independent members, the board is dominated by Klein and devoid of “genuine debate,” observes UC Berkeley Law professor Kenneth Taymor, who spent months studying the body.

Sacramento Bee, Nov. 24, 2008
http://www.sacbee.com/editorials/story/1422312.html

Taymor, who has been watching the institute’s operations for three years, noted that nearly everyone on the institute’s governing board—medical school deans, university officials—has some sort of financial interest in the grants being awarded. Even with officials recusing themselves, the board’s deliberations, he said, have the feel of “a club that was allocating money among themselves” based on preordained decisions.

Nature.com, March 17, by Erika Check Hayden
http://www.nature.com/news/2008/080317/full/452265b.html

“The re-examination has strengthened WARF’s [Wisconsin Alumni Research Foundation] position,” Taymor says. “It has deflected attention from the downstream patent landscape that WARF and Geron have created, and which is much more critical to commercialization than the fundamental patents.”